Is satelizumab (Anshiping) on u200bu200bthe market?

Satralizumab (Satralizumab) was first approved in Canada in June 2020 for the treatment of patients with AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). It was subsequently approved in Switzerland and Japan, and was approved for use by the U.S. Food and Drug Administration (FDA) in August 2020, becoming the third FDA-approved treatment for neuromyelitis optica spectrum disorder. Satclizumab is sold overseas under the trade name ENSPRYNG.

Satlizumab is effective in preventing relapse in patients with neuromyelitis optica spectrum disorder over the age of 12 years. Because the disability associated with neuromyelitis optica spectrum disorder is severe and worsens with relapse, satelizumab is thought to be beneficial in these patients. Neuromyelitis optica spectrum disorder is a rare disease, so the drug was tested in a small number of participants; however, the drug's safety profile was considered manageable, with the most common side effects being headache, joint pain, hyperlipidemia, decreased white blood cell levels, and injection-related reactions.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in the scope of Class B medical insurance. Only patients who meet the indications can be reimbursed. The specification is 120mg (1ml) per The price of a box may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.